ALNY:NSD-Alnylam Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 200.16

Change

-9.23 (-4.41)%

Market Cap

USD 25.13B

Volume

1.68M

Avg Analyst Target

USD 222.67 (+11.24%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

ALNY Stock Forecast & Price:
Based on the Alnylam Pharmaceuticals Inc stock forecasts from 16 analysts, the average analyst target price for Alnylam Pharmaceuticals Inc is USD 222.67 over the next 12 months. Alnylam Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Alnylam Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Alnylam Pharmaceuticals Inc’s stock price was USD 200.16. Alnylam Pharmaceuticals Inc’s stock price has changed by -0.31% over the past week, -4.67% over the past month and +6.01% over the last year.

About Alnylam Pharmaceuticals Inc (ALNY:NSD)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metaboli ...Read More

Company Website : https://www.alnylam.com

Address : 675 West Kendall Street, Cambridge, MA, United States, 02142

Employees : 1,665

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.57

52 Week High : 236.80

Short Ratio : 4.25

52 Week Low : 117.58

Shorted Shares : 4,383,940

200 Day Moving Average : 163.12

Shorted Shares Previous Month : 4,203,980

50 Day Moving Average : 201.92

Shares Held By Insiders : 0.54%

Short Percentage : 4.31%

Shares Held by Institutions : 100.95%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

-2.95 (-0.43%)

 USD76.14B 13.80 10.63
VRTX Vertex Pharmaceuticals Inc

-3.26 (-1.11%)

 USD73.02B 23.28 15.15
MRNA Moderna Inc

+0.18 (+0.15%)

 USD46.19B 3.66 2.45
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

+1.28 (+0.96%)

 USD30.98B 2.87 1.32
RPRX Royalty Pharma Plc

-0.15 (-0.37%)

 USD27.19B 39.06 19.32
SGEN Seagen Inc

+1.13 (+0.83%)

 USD25.40B 55.02 -36.47
GMAB Genmab AS

+0.20 (+0.63%)

 USD21.66B 41.88 3.47
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
ARGX argenx NV ADR

-4.50 (-1.26%)

 USD20.19B N/A -19.35

ETFs Containing ALNY

Symbol Name Weight Mer Price(Change) Market Cap
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

+0.31 (+0.69%)

 USD0.02B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

-0.06 (-0.17%)

 USD0.06B
GNOM Global X Genomics & Biote.. 0.00 % 0.50 %

+0.10 (+0.80%)

 USD0.21B
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.49 %

N/A

 USD0.03B
GERM ETFMG Treatments Testing .. 0.00 % 0.68 %

-0.10 (-0.50%)

 USD0.02B
BMED BlackRock Future Health E.. 0.00 % 0.85 %

-0.08 (-0.40%)

 USD7.09M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.03% 92% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.03% 91% A- 95% A
Trailing 12 Months  
Capital Gain 3.88% 91% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.88% 91% A- 90% A-
Trailing 5 Years  
Capital Gain 70.36% 83% B 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.36% 83% B 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 16.49% 76% C 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.49% 76% C 76% C
Risk Return Profile  
Volatility (Standard Deviation) 39.27% 58% F 38% F
Risk Adjusted Return 41.99% 86% B 77% C+
Market Capitalization 25.13B 99% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 136.89 1% F 1% F
Price / Cash Flow Ratio -39.17 95% A 78% C+
EV/EBITDA -31.40 99% A+ 89% B+
Management Effectiveness  
Return on Equity -190.54% 14% F 8% F
Return on Invested Capital -57.29% 46% F 22% F
Return on Assets -13.06% 86% B 32% F
Debt to Equity Ratio 114.87% 16% F 19% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.25 47% F 36% F
Short Percent 4.31% 43% F 34% F
Beta 0.57 78% C+ 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.